• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

P.T.Jyothi Datta

Mumbai, Jan. 5

Sun Pharma’s efforts to reconcile the ongoing litigation with Taro Pharma by sending two amended proposals have been rebuffed by the Israeli generic-drugs maker.

“Our board has asked me to inform you that it did not view the two options set forth in your proposal as constructive, or even in the ball-park,” said the Taro Chairman, Mr Barrie Levitt, in his letter to Sun Pharma’s Chairman and Managing Director, Mr Dilip Shanghvi.

“Both Sun’s merger proposal, as well as its tender offer alternative, involved prices that represented a significant reduction from the $10.25 price that Sun paid for Brandes’ eight per cent minority interest in Taro in February 2008, and which you proposed to pay in your revised merger proposal last May,” the letter said.

In its counter proposal, Taro’s management said that, among other things, it was willing to have a shareholder referendum on a merger price of Sun’s own choosing.

Taro’s management said it was hard to understand how Sun Pharma could expect that a proposal that valued the entire equity interest in Taro at less than what Sun paid for Brandes’ eight per cent interest nearly one year ago, would be a realistic starting point for “a good faith settlement negotiation to resolve the current impasse”.

Earlier in the day, Sun Pharma had outlined its two proposals, as directed by the Israel’s Supreme Court, in an effort to settle their on-going tussle. The court’s deadline was December 8.

Sun Pharma has agreed to amend the merger agreement and increase the consideration to $ 9.50/share. The initial price was at $ 7.75. But Taro would have to withdraw its termination of the merger agreement, Sun Pharma had said.

Sun Pharma too could terminate the merger agreement if the Israeli injunction prohibiting the closing of the tender offer was not lifted in 30 days or is reinstated at any time, the note had said. But in such a case, Sun Pharma will conditionally agree to pay promoters Levitt/Moros $ 8.75/ordinary share on closing the option agreement, it added. In its second option, Sun Pharma raised the tender offer price to $ 9 for all non-Levitt shareholders.

Through the first option, Sun Pharma would have gained 100 per cent control of Taro, while the second option would see its stake in Taro increase, a company spokesperson said.

Sun Pharma at present holds 36 per cent in Taro, while the Levitt/Moros family holds 12 per cent.

Taro had unilaterally terminated Sun Pharma’s $ 454 million proposal to acquire it, a year after the deal was formalised in 2007. The deal then went into litigation in Israel and the US.

More Stories on : Pharmaceuticals | Mergers & Acquisitions | Sun Pharmaceutical Industries Ltd | Overseas Investments

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line